Abstract
Insulin resistance is a major disorder that links obesity to type 2 diabetes mellitus (T2D). It involves defects in the insulin actions owing to a reduced ability of insulin to trigger key signaling pathways in major metabolic tissues. The pathogenesis of insulin resistance involves several inhibitory molecules that interfere with the tyrosine phosphorylation of the insulin receptor and its downstream effectors. Among those, growing interest has been developed toward the protein tyrosine phosphatases (PTPs), a large family of enzymes that can inactivate crucial signaling effectors in the insulin signaling cascade by dephosphorylating their tyrosine residues. Herein we briefly review the role of several PTPs that have been shown to be implicated in the regulation of insulin action, and then focus on the Src homology 2 (SH2) domain-containing SHP1 and SHP2 enzymes, since recent reports have indicated major roles for these PTPs in the control of insulin action and glucose metabolism. Finally, the therapeutic potential of targeting PTPs for combating insulin resistance and alleviating T2D will be discussed.
Similar content being viewed by others
Abbreviations
- aPKC:
-
Atypical protein kinase C
- ABC:
-
ATP binding cassette transporter
- ACD:
-
Acyl CoA dehydrogenases
- ACO:
-
Acyl CoA oxidase
- AGC:
-
Protein kinase A G, and C
- Akt:
-
Protein kinase B
- AP:
-
Adaptor protein
- aPKC:
-
Atypical protein kinase C
- AT2:
-
Angiotensin II subtype 2 receptor
- Cbl:
-
Casitas B-lineage lymphoma
- Cdk:
-
Cyclin-dependent kinase
- CEA:
-
Carcinoembryonic antigen
- CEACAM:
-
CEA-related adhesion molecules
- CNS:
-
Central nervous system
- COP1:
-
Caspase recruitment domain-containing protein 16
- CPT:
-
Carnitine palmitoyl transferase
- CVD:
-
Cardiovascular diseases
- ER:
-
Endoplasmic reticulum
- FA:
-
Fatty acids
- FAS:
-
Fatty acid synthase
- FFA/NEFA:
-
Free fatty acids/non-esterified FA
- Fkhr/FoxO1:
-
Forkhead transcription factor
- G6Pase:
-
Glucose-6-phosphatase
- Gab:
-
Grb2-associated-binding protein
- GLP:
-
Glucagon-like peptide
- GLUT:
-
Glucose transporter
- Grb2:
-
Growth factor receptor-bound protein 2
- GSK3:
-
Glycogen synthase kinase 3
- IGF:
-
Insulin growth factor
- IL:
-
Interleukin
- IR:
-
Insulin receptor
- IRR:
-
Insulin receptor-related receptor
- IRS:
-
Insulin-receptor substrate
- JAK:
-
Janus kinase
- KO:
-
Knockout
- LAR:
-
Leukocyte common antigen-related (phosphatase)
- LMW-PTP:
-
Low molecular weight PTP
- MAPK/ERK:
-
Mitogen activated protein kinase/Extracellular signal-regulated kinase
- MCK:
-
Muscle creatine kinase
- MEK:
-
MAPK kinase
- mRNA:
-
Messenger ribonucleic acid
- mTORC:
-
Mammalian TOR complex
- NAFLD:
-
Non-alcoholic fatty liver disease
- NEFA:
-
Non-esterified fatty acids
- NO:
-
Nitric oxide
- p60dok :
-
60-kDa tyrosine phosphorylated protein
- PAF:
-
RNA polymerase II associated factor
- PDK:
-
PDH kinase or Phosphoinositide-dependent kinase
- PGC-1:
-
PPARγ co-activator 1
- PH:
-
Pleckstrin homology
- PHLPP:
-
PH-domain leucine-rich repeat protein phosphatase
- PI3K:
-
Phosphatidylinositol 3-kinase
- PIP2:
-
Phosphotidylinositol-4,5-bisphosphate
- PIP3:
-
Phosphotidylinositol-3,4,5-triphosphate
- PKB:
-
Protein kinase B (also known as Akt)
- PM:
-
Plasmic membrane
- PP:
-
Protein phosphatase
- PPAR:
-
Peroxisome proliferator-activated receptor
- Prep:
-
PBX-regulating protein
- PTB:
-
Phospho-tyrosine binding domain
- PTEN:
-
Phosphatase with sequence homology to protein-tyrosine phosphatases and the cytoskeleton protein tensin
- PTP:
-
Protein tyrosine phosphatase
- Raf:
-
Proto-oncogene serine/threonine-protein kinase
- Ras:
-
G-protein and/or a family of related proteins discovered from rat sarcoma
- RPTP:
-
Receptor-like PTP
- RTK:
-
Receptor tyrosine kinases
- S6K1:
-
S6 kinase 1
- SCD:
-
Stearoyl-CoA desaturase
- SH:
-
Src homology
- Shc:
-
SH2-domain containing proteins
- SHP:
-
2-SH2-domain containing protein tyrosine phosphatase
- SNARE:
-
Soluble NSF attachment protein receptor
- SOS:
-
Son-of-sevenless exchange protein
- SREBP:
-
Sterol response element binding protein
- STAT:
-
Signal transducer and activator of transcription
- STP:
-
Serine/threonine phosphatase
- T2D:
-
Type 2 diabetes
- TAO:
-
Thousand and one amino acid kinase
- TC-PTP:
-
T-cell PTP
- TF:
-
Transcription factors
- TNF:
-
Tumor necrosis factor
- TOR:
-
Target of rapamycin
- WHO:
-
World Health Organization
- Wnt:
-
Wingless and int-1
References
Waxman A. WHO global strategy on diet, physical activity and health. Food Nutr Bull. 2004;25(3):292–302.
O’Sullivan JB, Mahan CM. Blood sugar levels, glycosuria, and body weight related to development of diabetes mellitus. The Oxford epidemiologic study 17 years later. JAMA. 1965;194(6):587–92.
Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham study. Am J Epidemiol. 1981;114(5):697–704.
Weyer C et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930–5.
McKenney RL, Short DK. Tipping the balance: the pathophysiology of obesity and type 2 diabetes mellitus. Surg Clin N Am. 2011;91(6):1139–48. vii.
McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339–50.
Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2006;12(1):75–80.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.
Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852–71.
Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008;94(2):206–18.
Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443–55.
Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–20.
Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–81.
Opie LH, Walfish PG. Plasma free fatty acid concentrations in obesity. N Engl J Med. 1963;268:757–60.
Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand. 1969;185(4):351–6.
Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60(10):2441–9.
Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139–43.
Randle PJ et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785–9.
Pan DA et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983–8.
Roden M et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97(12):2859–65.
Boden G et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab. 2002;283(1):E12–9.
Lam TK et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab. 2003;284(5):E863–73.
Wu N et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo. Diabetes Res Clin Pract. 2010;90(3):288–96.
Morita S, et al. Effect of exposure to non-esterified fatty acid on progressive deterioration of insulin secretion in patients with Type 2 diabetes: a long-term follow-up study. Diabet Med. 2012;29(8):980–5.
Koyama K et al. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol. 1997;273(4 Pt 1):E708–13.
Oprescu AI et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes. 2007;56(12):2927–37.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.
Tremblay F et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A. 2007;104(35):14056–61.
Klip A, Paquet MR. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care. 1990;13(3):228–43.
Heuson JC, Coune A, Heimann R. Cell proliferation induced by insulin in organ culture of rat mammary carcinoma. Exp Cell Res. 1967;45(2):351–60.
Wang W et al. Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev Cell. 2009;16(5):764–71.
Pause A et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371(6500):762–7.
Fulzele K et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309–19.
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.
Buchanan KD, Mawhinney WA. Insulin control of glucagon release from insulin-deficient rat islets. Diabetes. 1973;22(11):801–3.
Koch L et al. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest. 2008;118(6):2132–47.
Konner AC et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab. 2011;13(6):720–8.
Bruning JC et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122–5.
Fisher SJ et al. Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes. 2005;54(5):1447–51.
Hill JW et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11(4):286–97.
Konner AC et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007;5(6):438–49.
Lee JC, Downing SE. Effects of insulin on cardiac muscle contraction and responsiveness to norepinephrine. Am J Physiol. 1976;230(5):1360–5.
Maier S et al. Stimulation of L-type Ca2+ current in human atrial myocytes by insulin. Cardiovasc Res. 1999;44(2):390–7.
Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension. 1992;19(1 Suppl):I78–82.
Alvestrand A et al. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol. 1984;246(2 Pt 1):E174–80.
Breen DM, Giacca A. Effects of insulin on the vasculature. Curr Vasc Pharmacol. 2011;9(3):321–32.
Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;146(5):682–95.
Muller D et al. Identification of insulin signaling elements in human beta-cells: autocrine regulation of insulin gene expression. Diabetes. 2006;55(10):2835–42.
Kulkarni RN et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96(3):329–39.
Lim GE et al. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. 2009;150(2):580–91.
Kovacina KS, Roth RA. Characterization of the endogenous insulin receptor-related receptor in neuroblastomas. J Biol Chem. 1995;270(4):1881–7.
Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology. 2001;142(5):1685–8.
Patti ME, Kahn CR. The insulin receptor–a critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol. 1998;9(2–4):89–109.
De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769–83.
Lizcano JM, Alessi DR. The insulin signalling pathway. Curr Biol. 2002;12(7):R236–8.
Zhang-Sun G et al. A 60-kilodalton protein in rat hepatoma cells overexpressing insulin receptor was tyrosine phosphorylated and associated with Syp, phophatidylinositol 3-kinase, and Grb2 in an insulin-dependent manner. Endocrinology. 1996;137(7):2649–58.
Moodie SA, Alleman-Sposeto J, Gustafson TA. Identification of the APS protein as a novel insulin receptor substrate. J Biol Chem. 1999;274(16):11186–93.
Pronk GJ et al. Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins. J Biol Chem. 1993;268(8):5748–53.
Huang C et al. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J Biol Chem. 2005;280(19):19426–35.
Previs SF et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem. 2000;275(50):38990–4.
Kido Y et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000;105(2):199–205.
Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest. 2002;32 Suppl 3:3–13.
Sadagurski M et al. Insulin receptor substrate 2 plays diverse cell-specific roles in the regulation of glucose transport. J Biol Chem. 2005;280(15):14536–44.
Withers DJ et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391(6670):900–4.
Yamauchi T et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol. 1996;16(6):3074–84.
Tamemoto H et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 1994;372(6502):182–6.
Araki E et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994;372(6502):186–90.
Kubota N et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 2008;8(1):49–64.
Tsuruzoe K et al. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol Cell Biol. 2001;21(1):26–38.
White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182(1–2):3–11.
Backer JM et al. Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J Biol Chem. 1992;267(2):1367–74.
Lietzke SE et al. Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol Cell. 2000;6(2):385–94.
Peterson RT, Schreiber SL. Kinase phosphorylation: keeping it all in the family. Curr Biol. 1999;9(14):R521–4.
Mackay DJ, Hall A. Rho GTPases. J Biol Chem. 1998;273(33):20685–8.
Ziegler SF et al. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene. 1993;8(3):663–70.
Alessi DR et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261–9.
Stephens L et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279(5351):710–4.
Sarbassov DD et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–101.
Paz K et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem. 1999;274(40):28816–22.
Standaert ML et al. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem. 1997;272(48):30075–82.
Chou MM et al. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol. 1998;8(19):1069–77.
Scott PH et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998;95(13):7772–7.
Cross DA et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785–9.
Li X et al. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature. 2007;447(7147):1012–6.
Nakae J, Park BC, Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem. 1999;274(23):15982–5.
Cook SA et al. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem. 2002;277(25):22528–33.
Yoon JC et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131–8.
Puigserver P et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550–5.
Boulton TG et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65(4):663–75.
Lazar DF et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270(35):20801–7.
Noguchi T et al. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol Cell Biol. 1994;14(10):6674–82.
Sasaoka T et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem. 1994;269(18):13689–94.
Moscat J, Diaz-Meco MT. Feedback on fat: p62-mTORC1-autophagy connections. Cell. 2011;147(4):724–7.
Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A. 2001;98(13):7037–44.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84.
Peterson TR et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–86.
Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731–45.
Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal. 2009;2(67):pe27.
Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009;19(22):R1046–52.
Avruch J et al. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2009;296(4):E592–602.
Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28(11):573–6.
Nave BT et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344(Pt 2):427–31.
Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol. 2006;26(1):63–76.
Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001;276(41):38052–60.
Tremblay F et al. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology. 2005;146(3):1328–37.
Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171–6.
Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621–5.
Ogg S, Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell. 1998;2(6):887–93.
Wada T et al. Role of the Src homology 2 (SH2) domain and C-terminus tyrosine phosphorylation sites of SH2-containing inositol phosphatase (SHIP) in the regulation of insulin-induced mitogenesis. Endocrinology. 1999;140(10):4585–94.
Lazar DF, Saltiel AR. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov. 2006;5(4):333–42.
Sigal YJ, McDermott MI, Morris AJ. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem J. 2005;387(Pt 2):281–93.
Mistafa O et al. Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem. 2010;285(36):27900–10.
Finck BN et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006;4(3):199–210.
Peterson TR et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408–20.
Armstrong CG, Doherty MJ, Cohen PT. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem J. 1998;336(Pt 3):699–704.
Wong RH, Sul HS. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr Opin Pharmacol. 2010;10(6):684–91.
Galbo T et al. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. PLoS One. 2011;6(11):e27424.
Yan L, et al. The B55α-containing PP2A holoenzyme dephosphorylates FOXO1 in islet β-cells under oxidative stress. Biochem J. 2012;444(2):239–47.
Andreozzi F et al. Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance. Diabetologia. 2011;54(7):1879–87.
Xiao L et al. Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ. 2010;17(9):1448–62.
Andjelkovic M et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A. 1996;93(12):5699–704.
Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18(1):13–24.
Brautigan DL, Bornstein P, Gallis B. Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn. J Biol Chem. 1981;256(13):6519–22.
Schaapveld R, Wieringa B, Hendriks W. Receptor-like protein tyrosine phosphatases: alike and yet so different. Mol Biol Rep. 1997;24(4):247–62.
Alonso A et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117(6):699–711.
Koren S, Fantus IG. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 2007;21(4):621–40.
Hashimoto N et al. Insulin receptor protein-tyrosine phosphatases. Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. J Biol Chem. 1992;267(20):13811–4.
Frangioni JV et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992;68(3):545–60.
Egawa K et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J Biol Chem. 2001;276(13):10207–11.
Goldstein BJ et al. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem. 2000;275(6):4283–9.
Dubois MJ et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med. 2006;12(5):549–56.
Kuhne MR et al. Dephosphorylation of insulin receptor substrate 1 by the tyrosine phosphatase PTP2C. J Biol Chem. 1994;269(22):15833–7.
Kulas DT et al. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem. 1995;270(6):2435–8.
Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14(3):141–8.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.
Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006;116(7):1761–6.
Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9.
Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900–17.
Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(2):92–103.
Patel N, Huang C, Klip A. Cellular location of insulin-triggered signals and implications for glucose uptake. Pflugers Arch. 2006;451(4):499–510.
Filippi BM et al. Insulin activates Erk1/2 signaling in the dorsal vagal complex to inhibit glucose production. Cell Metab. 2012;16(4):500–10.
Ozcan L et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51.
Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. J Biol Chem. 1997;272(1):448–57.
Norris K et al. Expression of protein-tyrosine phosphatases in the major insulin target tissues. FEBS Lett. 1997;415(3):243–8.
Zhang WR et al. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol. 1996;10(5):575–84.
Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Cell Signal. 1996;8(7):467–73.
Ren JM et al. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes. 1998;47(3):493–7.
Zabolotny JM et al. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad Sci U S A. 2001;98(9):5187–92.
Ahmad F, Considine RV, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest. 1995;95(6):2806–12.
Ahmad F, Goldstein BJ. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism. 1995;44(9):1175–84.
Um JW, Ko J. LAR-RPTPs: synaptic adhesion molecules that shape synapse development. Trends Cell Biol. 2013;23(10):465–75.
Garcia-San Frutos M et al. Involvement of protein tyrosine phosphatases and inflammation in hypothalamic insulin resistance associated with ageing: effect of caloric restriction. Mech Ageing Dev. 2012;133(7):489–97.
Elchebly M et al. Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat Genet. 1999;21(3):330–3.
Wallace MJ et al. Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTPsigma. Nat Genet. 1999;21(3):334–8.
Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology (Bethesda). 2009;24:159–70.
Hendriks WJ, Pulido R. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochim Biophys Acta. 2013;1832(10):1673–96.
Tagami S et al. Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. Tohoku J Exp Med. 2002;197(3):169–81.
Gonzalez-Rodriguez A et al. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell. 2012;11(2):284–96.
Zabolotny JM et al. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem. 2008;283(21):14230–41.
Elchebly M et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283(5407):1544–8.
Delibegovic M et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 2009;58(3):590–9.
Agouni A, et al. Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem J. 2011;438(2):369–78.
Owen C et al. Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice. Diabetologia. 2013;56(10):2286–96.
Bakke J et al. Regulation of the SNARE-interacting protein Munc18c tyrosine phosphorylation in adipocytes by protein-tyrosine phosphatase 1B. Cell Commun Signal. 2013;11(1):57.
Song DD et al. Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNFalpha action in obesity. Biochim Biophys Acta. 2013;1831(8):1368–76.
Owen C et al. Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS One. 2012;7(2):e32700.
Delibegovic M et al. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol. 2007;27(21):7727–34.
Picardi PK et al. Modulation of hypothalamic PTP1B in the TNF-alpha-induced insulin and leptin resistance. FEBS Lett. 2010;584(14):3179–84.
Zhang J et al. Protein tyrosine phosphatase 1B deficiency ameliorates murine experimental colitis via the expansion of myeloid-derived suppressor cells. PLoS One. 2013;8(8):e70828.
Nasimian A et al. Protein tyrosine phosphatase 1B (PTP1B) modulates palmitate-induced cytokine production in macrophage cells. Inflamm Res. 2013;62(2):239–46.
Xu H et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol Immunol. 2008;45(13):3545–52.
Pandey NR et al. The LIM domain only 4 protein is a metabolic responsive inhibitor of protein tyrosine phosphatase 1B that controls hypothalamic leptin signaling. J Neurosci. 2013;33(31):12647–55.
Bettaieb A et al. Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and T cell protein tyrosine phosphatase. J Biol Chem. 2011;286(11):9225–35.
White CL et al. HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms. Am J Physiol Endocrinol Metab. 2009;296(2):E291–9.
Bence KK et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med. 2006;12(8):917–24.
Banno R et al. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J Clin Invest. 2010;120(3):720–34.
Gu F et al. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem. 2004;279(48):49689–93.
Snider NT, Park H, Omary MB. A conserved rod domain phosphotyrosine that is targeted by the phosphatase PTP1B promotes keratin 8 insolubility and filament organization. J Biol Chem. 2013;288(43):31329–37.
Chiarugi P et al. LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Biochem Biophys Res Commun. 1997;238(2):676–82.
Pandey SK et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem. 2007;282(19):14291–9.
Cho CY et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006;3(5):367–78.
Moller NP et al. Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon. J Biol Chem. 1995;270(39):23126–31.
Lammers R, Moller NP, Ullrich A. The transmembrane protein tyrosine phosphatase alpha dephosphorylates the insulin receptor in intact cells. FEBS Lett. 1997;404(1):37–40.
Cong LN et al. Overexpression of protein tyrosine phosphatase-alpha (PTP-alpha) but not PTP-kappa inhibits translocation of GLUT4 in rat adipose cells. Biochem Biophys Res Commun. 1999;255(2):200–7.
Kapp K et al. The protein tyrosine phosphatase alpha modifies insulin secretion in INS-1E cells. Biochem Biophys Res Commun. 2003;311(2):361–4.
Arnott CH et al. Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphatase alpha. J Biol Chem. 1999;274(37):26105–12.
Le HT, Ponniah S, Pallen CJ. Insulin signaling and glucose homeostasis in mice lacking protein tyrosine phosphatase alpha. Biochem Biophys Res Commun. 2004;314(2):321–9.
Andersen JN et al. Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling. Biochem J. 2001;354(Pt 3):581–90.
Aga-Mizrachi S et al. Cytosolic protein tyrosine phosphatase-epsilon is a negative regulator of insulin signaling in skeletal muscle. Endocrinology. 2008;149(2):605–14.
Faisal A et al. Serine/threonine phosphorylation of ShcA. Regulation of protein-tyrosine phosphatase-pest binding and involvement in insulin signaling. J Biol Chem. 2002;277(33):30144–52.
Galic S et al. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Mol Cell Biol. 2003;23(6):2096–108.
Xu J et al. Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int. 2007;31(1):88–91.
Fukushima A et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes. 2010;59(8):1906–14.
Loh K et al. T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice. Diabetologia. 2012;55(2):468–78.
Zee T et al. T-cell protein tyrosine phosphatase regulates bone resorption and whole-body insulin sensitivity through its expression in osteoblasts. Mol Cell Biol. 2012;32(6):1080–8.
Rajshankar D et al. Role of PTPalpha in the destruction of periodontal connective tissues. PLoS One. 2013;8(8):e70659.
Tiganis T. PTP1B and TCPTP–nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013;280(2):445–58.
Loh K et al. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab. 2011;14(5):684–99.
Tsui HW et al. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet. 1993;4(2):124–9.
Shultz LD et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73(7):1445–54.
Qu CK. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta. 2002;1592(3):297–301.
Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal. 2005;17(11):1323–32.
Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22(11):1251–67.
Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995;27(1):165–73.
Jin YJ, Yu CL, Burakoff SJ. Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity. J Biol Chem. 1999;274(40):28301–7.
Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992;12(2):836–46.
Horvat A et al. A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system. J Neurosci. 2001;21(3):865–74.
Lurie DI et al. Tyrosine phosphatase SHP-1 immunoreactivity increases in a subset of astrocytes following deafferentation of the chicken auditory brainstem. J Comp Neurol. 2000;421(2):199–214.
Massa PT et al. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia. 2000;29(4):376–85.
Kim HY et al. Raft-mediated Src homology 2 domain-containing proteintyrosine phosphatase 2 (SHP-2) regulation in microglia. J Biol Chem. 2006;281(17):11872–8.
Valencia AM et al. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. FEBS Lett. 1997;406(1–2):42–8.
Vogel W et al. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science. 1993;259(5101):1611–4.
Yang J et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278(8):6516–20.
Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992;89(3):1123–7.
Ren L et al. Substrate specificity of protein tyrosine phosphatases 1B, RPTPalpha, SHP-1, and SHP-2. Biochemistry. 2011;50(12):2339–56.
Yang J et al. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem. 1998;273(43):28199–207.
Liu W, et al. Identification of cryptotanshinone as an inhibitor of Oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem. 2013;56(18):7212–21.
Pei D et al. Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. Biochemistry. 1994;33(51):15483–93.
Zhao Z et al. Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem. 1993;268(4):2816–20.
Bennett AM et al. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A. 1994;91(15):7335–9.
Frank C et al. Effective dephosphorylation of Src substrates by SHP-1. J Biol Chem. 2004;279(12):11375–83.
Uchida T et al. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem. 1994;269(16):12220–8.
Hsu MF, Meng TC. Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem. 2009;285(11):7919–28.
Ozawa T et al. Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells. Int Immunol. 2007;19(9):1049–61.
Tenev T et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol. 2000;79(4):261–71.
Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem. 1997;272(28):17694–702.
Yang W, Tabrizi M, Yi T. A bipartite NLS at the SHP-1 C-terminus mediates cytokine-induced SHP-1 nuclear localization in cell growth control. Blood Cells Mol Dis. 2002;28(1):63–74.
Craggs G, Kellie S. A functional nuclear localization sequence in the C-terminal domain of SHP-1. J Biol Chem. 2001;276(26):23719–25.
Watanabe N, et al. Heterogeneous nuclear ribonucleoprotein Q (hnRNP Q) is a novel substrate of SH2 domain-containing phosphatase-2 (SHP2). J Biochem. 2013;154(5):475–80.
Xu E, et al. Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. Diabetes. 2012;61(8):1949–58.
Yu Z et al. SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem. 1998;273(6):3687–94.
Cuevas BD et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem. 2001;276(29):27455–61.
Lu Y et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003;278(41):40057–66.
Cui TX et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol. 2002;16(9):2113–23.
Bergeron S et al. Inhibition of the protein tyrosine phosphatase SHP-1 increases glucose uptake in skeletal muscle cells by augmenting insulin receptor signaling and GLUT4 expression. Endocrinology. 2011;152(12):4581–8.
Oriente F et al. Prep1 controls insulin glucoregulatory function in liver by transcriptional targeting of SHP1 tyrosine phosphatase. Diabetes. 2011;60(1):138–47.
Fiset A et al. Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and regulates insulin internalization. Cell Signal. 2011;23(5):911–9.
Kahn CR et al. Quantitative aspects of the insulin-receptor interaction in liver plasma membranes. J Biol Chem. 1974;249(7):2249–57.
Jaspan JB et al. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 1981;240(3):E233–44.
Sato H et al. Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. Diabetologia. 1991;34(9):613–21.
Burgess JW et al. Pharmacological doses of insulin equalize insulin receptor phosphotyrosine content but not tyrosine kinase activity in plasmalemmal and endosomal membranes. Biochem Cell Biol. 1992;70(10–11):1151–8.
Bergeron JJ et al. Uptake of insulin and other ligands into receptor-rich endocytic components of target cells: the endosomal apparatus. Annu Rev Physiol. 1985;47:383–403.
Yoshii H et al. Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am J Physiol Endocrinol Metab. 2006;290(6):E1089–97.
Kotronen A et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007;293(6):E1709–15.
Doherty 2nd JJ et al. Selective degradation of insulin within rat liver endosomes. J Cell Biol. 1990;110(1):35–42.
Backer JM, Kahn CR, White MF. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J Biol Chem. 1990;265(25):14828–35.
Di Guglielmo GM et al. Insulin receptor internalization and signalling. Mol Cell Biochem. 1998;182(1–2):59–63.
Valera Mora ME et al. Insulin clearance in obesity. J Am Coll Nutr. 2003;22(6):487–93.
Xu E et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology. 2009;150(8):3503–12.
Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab. 2002;13(6):240–5.
Huber M, Izzi L, Grondin P, Houde C, Kunath T, Veillette A, et al. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem. 1999;274(1):335–44.
Rocchi S et al. Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system. Endocrinology. 1996;137(11):4944–52.
Walchli S et al. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on “substrate-trapping” mutants. J Biol Chem. 2000;275(13):9792–6.
Maegawa H et al. SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Biochem Biophys Res Commun. 1996;228(1):122–7.
Arrandale JM et al. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem. 1996;271(35):21353–8.
Maegawa H et al. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. J Biol Chem. 1999;274(42):30236–43.
Fukunaga K et al. Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase. J Biol Chem. 2000;275(7):5208–13.
Tanaka S et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology. 1997;26(3):598–604.
Hayashi K et al. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. J Biol Chem. 2004;279(39):40807–18.
Mussig K et al. Shp2 is required for protein kinase C-dependent phosphorylation of serine 307 in insulin receptor substrate-1. J Biol Chem. 2005;280(38):32693–9.
Princen F et al. Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death. Mol Cell Biol. 2009;29(2):378–88.
Matsuo K et al. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. J Biol Chem. 2010;285(51):39750–8.
Nagata N et al. Hepatic Src homology phosphatase 2 regulates energy balance in mice. Endocrinology. 2012;153(7):3158–69.
Bettaieb A et al. Adipose-specific deletion of Src homology phosphatase 2 does not significantly alter systemic glucose homeostasis. Metabolism. 2011;60(8):1193–201.
He Z et al. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A. 2013;110(1):E79–88.
Yu J et al. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2. J Biol Chem. 2013;288(6):3823–30.
Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62.
Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol. 2006;6(8):602–12.
Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 2008;13:4925–32.
Tsou RC, Bence KK. Central regulation of metabolism by protein tyrosine phosphatases. Front Neurosci. 2012;6:192.
Takahashi A et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011;43(1):45–56.
Duchesne C et al. Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells. J Biol Chem. 2003;278(16):14274–83.
Simoneau M et al. SHP-1 inhibits beta-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal. 2011;23(1):269–79.
Liang LF et al. Cembrane diterpenoids from the soft coral Sarcophyton trocheliophorum Marenzeller as a new class of PTP1B inhibitors. Bioorg Med Chem. 2013;21(17):5076–80.
Zhang W et al. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim Biophys Acta. 2006;1760(10):1505–12.
Hsu MF, Meng TC. Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem. 2010;285(11):7919–28.
Zhang S et al. A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc. 2012;134(43):18116–24.
Lorenzen JA, Dadabay CY, Fischer EH. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J Cell Biol. 1995;131(3):631–43.
Chughtai N et al. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem. 2002;277(34):31107–14.
Wu TR et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem. 2002;277(49):47572–80.
Wang Y et al. Proteomic analysis reveals novel molecules involved in insulin signaling pathway. J Proteome Res. 2006;5(4):846–55.
Kruger M et al. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A. 2008;105(7):2451–6.
Hornbeck PV et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2012;40(Database issue):D261–70.
Acknowledgments
This review was written based on a literature search and some studies performed by the authors and that were supported by a grant from the Canadian Institutes of Health Research.
Conflict of interest
Authors declare no conflict of interest or financial relationship with the organization that sponsored some of the research described in this review article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, E., Schwab, M. & Marette, A. Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. Rev Endocr Metab Disord 15, 79–97 (2014). https://doi.org/10.1007/s11154-013-9282-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11154-013-9282-4